DPP-4 inhibitors: a patent review (2012 - 2014). (Q38284522)

1 September 2017

1 reference

title

DPP-4 inhibitors: a patent review (2012 - 2014). (English)

1 reference

1 September 2017

3

1 reference

1 September 2017

Adriano Mollica

5

0 references

Ettore Novellino

object named as

Ettore Novellino

series ordinal

4

0 references

author name string

Roberto Costante

series ordinal

1

1 reference

PubMed ID

25482888

1 September 2017

Azzurra Stefanucci

series ordinal

2

1 reference

PubMed ID

25482888

1 September 2017

language of work or name

English

0 references

publication date

6 December 2014

1 reference

Expert Opinion on Therapeutic Patents

1 September 2017

1 reference

1 September 2017

25

1 reference

1 September 2017

2

1 reference

1 September 2017

209-236

1 reference

Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation

1 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

DPP-4 inhibitors and lipids: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

Sitagliptin reduces albuminuria in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

Sitagliptin: anti-platelet effect in diabetes and healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

Sitagliptin-induced hemolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

Angiotensin-converting enzyme and dipeptidyl peptidase IV inhibitors: an increased risk of angioedema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

Sitagliptin-associated angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

The placement of DPP-4 inhibitors in clinical practice recommendations for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

Recent advances in non-peptidomimetic dipeptidyl peptidase 4 inhibitors: medicinal chemistry and preclinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

Dipeptidyl peptidase-4 inhibitors: multitarget drugs, not only antidiabetes drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

Recent patents of dipeptidyl peptidase IV inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

Enzymatic and extraenzymatic role of ecto-adenosine deaminase in lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

CD26, let it cut or cut it down.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

Dipeptidyl peptidase IV activity and/or structure homologs: contributing factors in the pathogenesis of rheumatoid arthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

Prescribing gliptins: Enthusiasm should be coupled with caution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

Dipeptidyl peptidase expression during experimental colitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.991309

10.1517/13543776.2014.991309

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference

PubMed ID

25482888